Fifteen individual BDCs in this series. The range of outcomes is wide: ARCC at 1.15x NII coverage, PSEC cutting twice in 18 months while showing its best NII coverage yet. Six distribution changes across the group — FSK, GBDC, TSLX, NMFC, PFLT’s restructuring, and PSEC’s second cut. The broader BDC sector backdrop in 2026 has been rising nonaccruals, compressed floating-rate yields, and management teams choosing between defending income optics and building cushion.

Crescent Capital BDC is analytically the strangest case in the group.

Q1 2026 NII: $0.42/share. Old quarterly dividend: $0.42/share. Coverage: exactly 1.0x. Technically covered. And yet, the May 13, 2026 press release declared a Q2 2026 base dividend of $0.34 — a 19% reduction.

Every other cut in this series came with some version of an NII shortfall as the stated or visible driver. CCAP cut from exactly covered. That’s the question worth answering.

Quick Verdict

Factor	Details
Q1 2026 NII	$0.42/share — matched the old $0.42 quarterly rate at 1.0x coverage exactly
Q1 net income	($0.42)/share — unrealized/realized losses of ~$0.84/share fully offset NII
Old base dividend	$0.42/quarter
New base dividend	$0.34/quarter — 19% cut
NII coverage (new rate)	1.24x
Special dividends	$0.09 total; 3 quarterly $0.03 installments from UTI reserves
NAV	$18.27/share
Nonaccruals	4.1% of portfolio at cost / 2.0% at fair value
Fee reductions (Apr 1)	Base management 1.25%→1.00%; incentive 17.5%→15.0%
Investment income	$37.9M total; 9.8% weighted average portfolio yield
Net leverage	1.32x debt/equity; $26.6M cash + $206.2M undrawn capacity
Market price / NAV	~$12.38 market vs. $18.27 book — ~32% discount to NAV
Headline yield	~11% on $0.34 base
Earnings call	May 14, 2026 (today)
Management	External (Crescent Capital Group)
Passivity score	5/10

Best for: Investors who read the fee reductions as genuine manager alignment and believe CCAP’s 1.24x post-cut coverage gives adequate runway through the nonaccrual and portfolio loss headwinds already visible in Q1.

Skip if: You need distribution consistency. A covered cut signals forward portfolio concerns the trailing NII number doesn’t surface. The ~32% NAV discount is the market’s existing answer to how comfortable it is with that uncertainty.

What Is Crescent Capital BDC (CCAP)?

Crescent Capital BDC (NASDAQ: CCAP) is a Business Development Company externally managed by Crescent Capital Group LP, a large-scale alternative credit manager. CCAP focuses on first and second lien debt to U.S. upper middle-market companies, with a weighted average portfolio yield of 9.8% as of Q1 2026. NAV stands at $18.27/share while the stock trades near $12.38 (post-announcement), implying a roughly 32% discount to book.

The manager context matters here. Crescent Capital Group is not a boutique operation. Managing tens of billions in credit assets gives the manager visibility into middle-market credit conditions that most smaller BDC managers don’t have. When a manager at that scale proactively rebases a covered dividend while simultaneously cutting fees, it’s a specific, coordinated decision. Not an oversight.

That’s what makes CCAP analytically unusual in this series. Every other cut had a visible coverage gap compelling the action. CCAP’s Q1 NII covered the old $0.42 rate at exactly 1.0x. The cut happened anyway.

The Coverage Math: 1.0x Before, 1.24x After

How does CCAP’s Q1 2026 NII compare to both dividend rates?

Crescent Capital BDC reported Q1 2026 NII of $0.42/share. Against the old $0.42 quarterly dividend, NII coverage was exactly 1.0x — covered, but with zero buffer. Against the new $0.34 quarterly base dividend, NII coverage is 1.24x. The cut creates $0.08/share per quarter of additional headroom — $0.32/share annually — without NII changing at all. This is entirely a management decision to build cushion, not a response to an income shortfall.

Exactly 1.0x coverage is technically adequate. But only technically. Any single credit moving to nonaccrual, any origination fee income that doesn’t repeat, any incremental portfolio yield compression, and the old $0.42 rate shifts from “covered at 1.0x” to “covered at 0.97x.” At that point CCAP would be distributing from undistributed taxable income reserves to bridge the gap, which is sustainable for a quarter and then becomes a story management doesn’t want to tell.

The fee reductions (effective April 1, before the earnings release) and the dividend rebasing together suggest a coordinated income recalibration. Not an emergency. A judgment call.

That distinction matters for what comes next. When a BDC cuts because NII was inadequate, the question is whether NII recovers. When a BDC cuts from covered, the question is what management is seeing in forward portfolio quality that a trailing coverage ratio doesn’t yet show.

The $0.42 Net Loss: What NII Doesn’t Capture

Q1 NII of $0.42/share is an income statement figure: what the portfolio earned after expenses. Net income of ($0.42)/share is the bottom-line result after unrealized and realized gains and losses flow through. The $0.84/share difference between those two numbers is what the portfolio’s market value actually did in Q1.

Put plainly: CCAP’s portfolio earned $0.42/share in income and simultaneously lost $0.84/share in fair value. Net income: negative.

BDC dividends are paid from NII, not net income, so the portfolio losses don’t mechanically threaten the dividend directly. But three things follow from a quarter that size:

NAV erosion is real. Portfolio losses flow directly to NAV. At $18.27/share now, further loss quarters without recovery gradually reduce the asset base that portfolio yield applies to. A declining NAV compresses absolute dollar income generated even if the yield percentage holds steady. Enough quarters like Q1 and the 9.8% portfolio yield applies to a shrinking base.

Nonaccruals at 4.1%. The 4.1% nonaccrual rate at cost isn’t extreme by the standards of this series — GSBD ran 4.7%, BXSL hit 4.7%, FSK was above 5% pre-cut. But 4.1% nonaccruals in the same quarter that produced ($0.42) in net losses, against a dividend that was barely covered at 1.0x, is a picture where the margin is narrow. Any expansion from 4.1% toward 5-6% compresses NII further — and at the old $0.42 rate, “further” means “uncovered.”

The cut is forward-looking. This is what’s different about CCAP versus every other cut in this series. Management didn’t cut because they had to. They cut because Q1’s thin coverage margin wasn’t stable against the credit and portfolio dynamics already showing up in the net income figure. The covered cut is actually the more honest signal: we see what’s ahead and we’re not waiting to confirm it.

Fee Reductions: The Other Half of the Announcement

The dividend cut is the headline. The fee reductions effective April 1 are the more structurally interesting signal.

Base management fee: 1.25%→1.00%. Incentive fee: 17.5%→15.0%.

These came before the earnings release — and they’re reflected in the Q1 NII figure already. Without the lower fee structure, Q1 NII would have been lower than $0.42. The fee reductions increase the NII run rate permanently at the portfolio’s current size.

The math: a 25bps base fee reduction on a total portfolio of meaningful size produces real dollar savings annually flowing to shareholders instead of the manager. The incentive fee reduction adds savings on income above the hurdle. Combined, the fee cuts may add several cents per share annually in NII — not transformational, but meaningful enough to increase the cushion on the new $0.34 base rate.

Two ways to read management cutting fees alongside cutting the dividend:

The constructive read: Crescent Capital Group is absorbing pain alongside common shareholders. Their fee income is down, distributions to shareholders are down, and management is betting the rebased structure improves CCAP’s valuation over time — which benefits the manager too.

The skeptical read: The fee reductions were at least partly necessary to ensure the new $0.34 base produced coverage above 1.20x in the press release. Without the fee savings, the NII coverage at $0.34 might have been 1.10x rather than 1.24x. 1.24x is a cleaner story.

Both can be true simultaneously. The fee reductions are real and durable. The dividend cut is 19%. The combination creates more NII headroom than either action alone. No other BDC in this series cut management fees alongside the distribution change — that’s worth noting as a structural distinction, not necessarily as vindication.

The NAV Discount: ~32% Below Book

CCAP trades near $12.38 post-announcement. Book value is $18.27/share. Approximately a 32% discount to NAV.

The PSEC NAV discount situation is more extreme — 55% — driven by specific governance complexity and preferred stock obligations that CCAP doesn’t carry. CCAP’s ~32% discount is notable for a BDC that doesn’t have those structural complications.

A ~32% discount conveys something specific: the market doesn’t believe stated NAV fully represents what common shareholders would realize — or it’s pricing in continued NAV erosion. At $18.27 book value with ($0.42)/share net losses in Q1 alone, the erosion scenario is already active.

The discount also creates a numerical anomaly on the dividend that matters for how you evaluate the yield.

At $0.34/quarter, CCAP yields roughly 11% at the current ~$12.38 price. On NAV ($18.27), that same $0.34/quarter yields about 7.4%. What reads as an 11% yield on the screen is actually a 7.4% yield on the underlying asset base — a narrower spread than the discount implies, but still a meaningful premium to the NAV yield.

Investors buying CCAP at a ~32% NAV discount aren’t capturing 11% yield on assets worth $18.27. They’re capturing 7.4% yield on assets, plus a speculative position that the discount narrows. Those are different investments wearing the same yield number.

CCAP vs. the BDC Series

Fifteen posts. CCAP holds the analytically cleanest version of an unusual position: the first cut in this series where trailing NII coverage was technically adequate before the reduction.

	CCAP	NMFC	PSEC	ARCC	GSBD	FSK
Headline yield	~11%	~8-9%	~15%	~10%	~9%	~10%
Pre-cut NII coverage	1.0x (covered)	Covered w/waiver	~1.19x	1.15x	68.75%	~92-94%
Post-cut NII coverage	1.24x	Covered	1.52x (2nd cut)	1.15x (no cut)	68.75% (no cut)	~92-94%
Cut %	19%	22%	22% (2nd cut)	0%	0%	31%
Q1 net income	($0.42)/share	Negative	Negative	Positive	Negative	Negative
NAV discount	~32%	Moderate	~55%	Premium/par	Premium/above NAV	Large
Nonaccruals (cost)	4.1%	Below peers	Above peers	Normal	4.7%	~5%+ pre-cut
Fee reductions	Yes — Apr 1	No	No	No	No	No
Management	External (Crescent)	External	External	External (Ares)	External (Goldman)	External (FS/KKR)
Passivity score	5/10	5/10	4/10	8/10	5/10	4/10

The fee reduction is CCAP’s distinguishing move. No other BDC in this series cut management fees alongside the dividend. Whether that’s genuine alignment or coverage-ratio engineering — it’s real and durable, and it increases the NII available to common shareholders going forward.

The Tax Math

BDC dividends are ordinary income. No qualified dividend treatment.

At 35–37% federal marginal rates in a taxable account, CCAP’s ~11% headline yield compresses to approximately 6.9–7.2% after federal tax. That’s where municipal bonds compete directly for high-bracket investors — without a ~32% NAV discount, without ($0.42)/share net income losses in Q1, and without a recent 19% dividend cut as recent history.

T-bills at ~4.2% are the zero-credit-risk baseline. CCAP’s after-tax yield needs to clear it by enough margin to compensate for NAV erosion risk, 4.1% nonaccrual exposure, and an income base management just reduced by choice.

In a Roth or traditional IRA, ordinary income treatment disappears and ~11% is ~11% — plus the $0.03/quarter specials while UTI distributes across three quarters. Tax-advantaged accounts are where CCAP’s yield picture is cleanest. Running the full dividend investing math before allocating meaningful capital to CCAP in a taxable account is not optional; the ~32% NAV discount and Q1 net losses are not IRA problems, but they’re real portfolio problems either way.

Who Should Own CCAP

Investors who read fee reductions plus a covered rebasing as a signal management is recalibrating proactively rather than reactively. The move from 1.0x to 1.24x coverage creates real headroom. The fee cuts reduce the expense load permanently. If Q2 and Q3 NII holds near $0.42, the $0.34 base is comfortably covered through the near term without drawing on reserves.

Tax-advantaged investors sizing CCAP as a secondary BDC position at a discount. At ~32% below NAV, CCAP offers optionality on the discount narrowing over a multi-year horizon — not a certainty, but a scenario where consistent covered distributions and stabilizing credit quality gradually reduce the gap. In a Roth IRA, the ~11% yield (plus specials) compounds without the annual ordinary income leakage that makes the taxable case more complicated.

Who Should Skip CCAP

Anyone treating the 1.0x pre-cut coverage as proof the cut was unnecessary. Exactly covered is the narrowest possible margin before uncovered. Any single credit moving to nonaccrual from a 4.1% nonaccrual base, any fee income that doesn’t repeat — and the old rate becomes uncovered. Management saw what was ahead and decided the thin margin wasn’t stable.

Income investors who need distribution consistency. CCAP just cut 19% from a technically covered rate. The new $0.34 base is better covered — but the Q1 ($0.42)/share net loss means portfolio NAV is eroding while distributions are paid. Any investor prioritizing income stability over total return would find ARCC at 1.15x with no distribution cuts a more defensible position than CCAP at 1.24x post a covered cut with active portfolio impairments.

Investors interpreting the ~11% yield as a discount opportunity. CCAP’s headline yield is a function of the ~32% NAV discount — not excess income generation relative to asset value. The 7.4% yield on NAV context matters. Deep discounts persist when markets have specific reasons to price assets below book, and CCAP’s Q1 net losses plus 4.1% nonaccruals provide those reasons.

The Bottom Line

CCAP’s Q1 2026 report presents the specific kind of unusual that this series hadn’t seen before: a manager choosing to cut a dividend NII technically covered, while simultaneously reducing their own fees, against a backdrop of ($0.42)/share net losses and 4.1% nonaccruals.

The 19% cut from 1.0x coverage is a forward-looking statement. Management saw enough in the Q1 credit picture — the losses, the nonaccrual level, the portfolio yield trajectory in a 3.75% fed funds environment — to decide that 1.0x was an insufficient cushion heading into Q2 and Q3. Fee reductions absorb part of the impact and increase NII headroom on the new rate. The UTI specials ($0.09 total across three quarters) soften the near-term income impact for existing holders.

The ~32% NAV discount is the market’s existing verdict on CCAP’s book value reliability. It predates this earnings release. The Q1 net income of ($0.42)/share — where NII was entirely consumed by portfolio impairments on a dollar-for-dollar basis — doesn’t improve that verdict.

Three things to watch going into Q2: whether the 4.1% nonaccrual rate expands or stabilizes — movement toward 5% would compress NII and test the new $0.34 rate directly. Whether NAV recovers from $18.27 or continues declining — each dollar of further erosion narrows the gap between what CCAP says it’s worth and what the market will pay. And what the May 14 earnings call commentary surfaces about forward portfolio credit quality beyond what the press release disclosed.

The covered cut is a cleaner signal than the market initially priced — CCAP declined approximately 5.5% on the announcement. A 19% dividend rebasing that creates 1.24x coverage from a permanently reduced expense structure is not a disaster. But it is management explicitly acknowledging that Q1’s thin coverage margin wasn’t stable, and the market had been saying the same thing at a ~32% NAV discount before the earnings ever dropped.

---

Q1 2026 financial results from the Crescent Capital BDC May 13, 2026 press release (GlobeNewswire). Additional context from BDC Investor’s CCAP coverage. BDC series comparisons sourced from prior posts in this series. This is not financial or investment advice. Verify current NAV, distribution rate, and nonaccrual data before making investment decisions.